Status and phase
Conditions
Treatments
Study type
Funder types
Identifiers
About
To evaluate the efficacy of long-term treatment with 2 mg aflibercept via different intravitreal (IVT) treatment regimens to participants with DME pretreated with 2 mg aflibercept every 8 weeks after 5 initial monthly injections for approximately 1 year or more (according to the EU label for the first year of treatment)
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
The subject's history of aflibercept treatment met all of the following:
To be met at initiation of pre-study aflibercept treatment:
Exclusion criteria
At initiation of pre-study aflibercept treatment:
At initiation of pre-study aflibercept treatment, screening for this study, and baseline for this study:
Primary purpose
Allocation
Interventional model
Masking
463 participants in 3 patient groups
Loading...
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal